×

RNS Number : 6976Y

Integumen PLC

10 May 2019

 

AIM share code: SKIN

 

Integumen PLC

("Integumen" or "Company")

 

Launch of Labskin human skin clone tests for Medical Device and Clinical Research trials

 

Combined with human volunteers doubles number of skin tests possible saving time and money

 

Integumen today announces the roll-out of the Labskin human clone skin testing platform into the medical device and clinical research sectors.

 

When combined with human volunteers, Labskin's AI platform creates double the number of skin tests possible that are more reliable and accurate than human volunteers alone. The Labskin test process transforms the cost structures of medical device and skin treatment clinical trial testing by:

 

·      50% reduction of human volunteers required for each trial;

·      Instantly creates a cloned twin of the human test subject;

·      Reduces recruitment time;

·      Cuts project management costs, supervision time and support personnel by up to 50%;

·      AI integration delivers reliable comparative analytical data plus human test response data;

·      Lowers error rate by reducing number of human volunteers who are not sticking to test regime;

·      Increases scientific accuracy and anecdotal evidence from human clone twin tests;

·      Real-time feedback through the Labskin AI platform to client; which,

·      Delivers fast results, lowers development costs and reduces time to market

 

The Integumen business model of collaboration with the Centre for Skin Sciences (CSS) in Bradford, UK, Sheffield Hallam University, UK, Cork Institute of Technology, Ireland, plus Integumen's own enlarged Labskin laboratories in York, UK, provides access to thousands of potential student volunteers with all sorts of skin diseases, reducing the recruitment process for specific young adult prone skin diseases.

 

Gerard Brandon, CEO of Integumen plc, comments:

 

"Regulatory pressures have increased the demand for skin testing in EU 2017/745 rule 21 and animal testing is now banned on skin related products in EU Directive 2003/15/EC enforced since March 2013.  As a trusted partner to our CRO (Contract Research Organisation) partners, our disruptive technology is able to enhance the margins of medical device and clinical trial organisations on test subjects.  Labskin can double the output of test results requiring fewer test volunteers and lower project management time, delivering faster, more reliable and consistent results for their skin care, health care, wound care and pharmaceutical clients, all at a lower cost to our partners." 

 

Contacts

 

Integumen plc	Gerard Brandon, CEO	+44 (0) 7340 055 643
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974
Turner Pope Investments (TPI) Limited (Broker)	Andy Thacker	+44 (0) 20 3621 4120

 

 

 

About Integumen:

 

Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

 

The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.

About RNS Reach announcements:

RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRASFEFFSFUSESI

Close

×

RNS Number : 8735X

Sativa Investments PLC

02 May 2019

 

 

Press Release

2 May 2019

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

 

Sativa Investments PLC

 

 ("Sativa" or "the Company" or "the Group")

 

Sativa to open first Goodbody & Blunt wellness centre in Bath with lease signed 

 

Sativa Investments PLC (NEX: SATI), the UK's first medicinal cannabis investment vehicle, is to open the first of its Goodbody & Blunt wellness centres in Bath and has leased a 60.67 sq. m (653 sq. ft) retail unit with frontage on to the prime, high footfall, Broad Street and Milson Place City-centre shopping destinations. 

 

The store will offer a wide range of Cannabidiol ("CBD") products and will include a café for customers to consume CBD infused coffee, tea and water.  Customers will also be able to buy CBD sport's energy shots and also specially selected CBD coffee and tea in bean form to take home and enjoy in their own environment. 

 

The UK is fast-recognising, along with North America and much of Europe, CBD as a valuable alternative medicine and treatment.  Sativa already has a well-established on-line and wholesale brand, George Botanicals, which has developed bespoke white label products for Goodbody & Blunt.  The store will also stock high quality CBD products from around the world.  Every item stocked by the Goodbody & Blunt stores will have passed rigorous industry-leading tests, conducted by Sativa's own PhytoVista Laboratories which analyses the quality and the levels of the CBD compound contained within products, both for its own sales and also third parties.  That analysis ensures that every stock item achieves full compliance within regulatory limits. 

 

The Bath store is the first of three pilot stores after which the Company intends to roll-out a national franchise network, because the Directors believe that this is the fastest and least capital-intensive route to a national footprint.  The Company feels a direct consumer relationship is very important in order to support its future franchisees and brand development. 

 

As announced in January 2019, the Goodbody & Blunt initiative is led by Chris Jones, a recognised retail expert whose experience includes the early deployment of the Phones 4U retail presence. 

 

In tandem with the launch of the Goodbody & Blunt chain, the Company is working closely with the Food Standards Authority (FSA) as it deliberates how to regulate CBD products, an initiative that Sativa welcomes and is delighted to assist in. 

 

Geremy Thomas, Chief Executive and founder, said:  "Sativa was first to market as a UK-quoted medical cannabis investment vehicle and continues to lead the way with its seed to consumer strategy.  Goodbody & Blunt's high-street CBD outlets will break with tradition, delivering high-end wellness centres with fully trained staff to advise on the quality and provenance of products.  

 

"Key value drivers to Sativa's business model include brand recognition and distribution, and the Goodbody & Blunt initiative provides both, alongside the Group's other brands of George Botanicals and PhytoVista laboratories. 

 

"Sativa is a full-spectrum Group of businesses within the medicinal cannabis and CBD industries, offering in-house validated testing alongside retail, and is progressing well with an R&D Home Office licence application that will facilitate the Company supplying Kings' College London with medicinal cannabis research product from its secure growing facility." 

 

The Bath store is expected to open in early summer 2019. 

 

The Directors of the Company accept responsibility for the contents of this announcement. 

 

–  Ends –

 

For further information please contact:

 

Geremy Thomas Founder & Chief Executive Officer Sativa Investments PLC +44 (0) 20 7971 1255 [email protected]	Joseph Colliver Chief Financial Officer Sativa Investments PLC +44 (0) 20 7971 1255 [email protected]
NEX Exchange Corporate Adviser Guy Miller and Lucy Williams Peterhouse Capital Limited  +44 (0) 20 7469 0930 [email protected]

 

Financial PR and IR Abchurch Communications Julian Bosdet   Abchurch Switchboard [email protected]

+44 (0) 20 7469 4630 www.abchurch-group.com

 

 

Notes to Editors

Sativa invests in well-placed ventures within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company's pan-European, end-to-end, seed-to-consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company's equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

 

Sativa Investments has already made six investments to date, these being Canada-based and dual-listed emerging pharmaceutical company, Veritas Pharma Inc. ("Veritas Pharma" or "Veritas"), CSE-listed Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc. ("RDT"), which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals Ltd (of which Sativa has 100 per cent ownership), PhytoVista Laboratories (of which Sativa also has 100 per cent ownership), a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil, a joint venture with Germany's Lexamed GmbH, and an option on a 7.53-acre development site in Wiltshire with the potential to build a glasshouse for growing raw cannabis for medicinal and CBD use. 

 

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company's Board and Medicinal Cannabis Advisory Board have a combined 60 years' industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency, which he has chaired, for the legalisation of medicinal cannabis in the UK  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativainvestments.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NEXGRGDUBUGBGCD

Close

×

RNS Number : 6537X

Osirium Technologies PLC

01 May 2019

 

 

 

For immediate release

1 May 2019

 

Osirium Technologies plc

 

("Osirium" or "Group")

 

Opus sets new benchmark in Privileged IT Process Automation

 

Osirium launches first secure solution to automate key IT processes and increase IT Service Desk productivity, while also improving corporate security

 

Osirium Technologies plc (AIM: OSI.L), a leading vendor of cloud-based cybersecurity software, today announces the immediate availability of Opus, its secure IT Process Automation solution.   

 

Opus builds on Osirium's proven success in Privileged Task Automation, providing a highly-flexible platform for automating essential IT processes.  The product has been designed to address currently unresolved challenges of overloaded IT teams, growing backlogs of customer requests and increasing needs to improve security.

 

David Guyatt, Chief Executive Officer of Osirium commented: "Traditional ways of automating IT processes are inflexible, risky and not fit for the security-conscious 21st century IT organisation.   IT Operations teams need a much better alternative, built from the ground-up to be fully secure and integrated for simple deployment and rapid speed to value.  They want the benefits of Robotic Process Automation, but with enterprise-grade security.  Opus delivers this by automating processes and controlling access to privileged accounts, addressing one of most critical enterprise security challenges facing CISOs, to remove uneccessary direct access to vulnerable privileged accounts. 

 

"Initial customer projects are focusing on IT Help Desks, principally transforming first call resolution performance by delegating help desk automation tasks to first line support teams – a practice now known as "shift-left" operations.  Looking further ahead, Osirium sees clear scope for automating additional process-driven environments, such as NetOps, DevOps and IoT.

 

"The Directors believe that the Opus product will contribute to a growing and material impact on Osirium's financial performance."

 

– Ends –

 

For further information:

Osirium Technologies plc	Tel: +44 (0) 118 324 2444
David Guyatt, Chief Executive Officer Rupert Hutton, Chief Financial Officer www.osirium.com
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)	Tel: +44 (0) 20 7710 7600
Fred Walsh / Neil Shah / Alex Price
Yellow Jersey PR (Financial PR) Sarah Hollins Henry Wilkinson	Tel: +44 (0)7764 947 137 Tel: +44 (0)7951 402 336

Notes to Editors:

 

About Osirium

Osirium Technologies plc (AIM: OSI.L) operates in one of the fastest growing parts of the cybersecurity market and is a leading vendor of Privileged Access Management ("PAM") software. Osirium's cloud-based products protect critical IT assets, infrastructure and devices by preventing targeted cyber-attacks from directly accessing Privileged Accounts, removing unnecessary access and powers of Privileged Account users, deterring legitimate Privileged Account users from abusing their roles and containing the effects of a breach if one does happen.

 

Osirium has defined and delivered what the Directors view as the next generation PAM solution.  The team has developed the concept of a Virtual Air Gap to separate users from passwords.  Built on Robotic Automation technology, Osirium's Privileged Task Management module further strengthens Privileged Account security by minimising the cyber-attack surface and delivering an impressive return on investment benefits for customers.

 

Founded in 2008 and with its headquarters in Reading, UK, the Group was admitted to AIM in April 2016.  For further information please visit www.osirium.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCKMGFDRGVGLZM

Close

×

RNS Number : 0095X

Integumen PLC

25 April 2019

 

AIM share code: SKIN

25 April 2019

Integumen PLC

("Integumen" or "Company")

 

Launch of New Animal-Free Labskin Dandruff Test

 

Labskin STOER study demonstrates 54% increase in skin rehydration in 24 hours
Promotion of new skin cells leaving fresher looking skin

 

Integumen today announces the completion of development and launch of a new dandruff test on its animal-free Labskin test platform.  The Company also reports additional successful results of research assessing the impact of STOER products on rehydration of the skin.

 

Unique Animal-Free Anti-Dandruff testing:

The new Labskin test uses a unique scalp variation that mimics skin bacteria and dandruff, in both healthy and 'itchy' states.  This allows for dandruff relief and scalp protection products to be tested effectively on a realistic human skin model in a laboratory setting without the need to test on animals.

 

Labskin full thickness human skin equivalent is suitable for testing irritation under guideline 439 of the OECD* (see below). Populating and growing bacteria, sourced from human scalp, onto Labskin, clearly demonstrates the effective response of the irritation and hydration tests. 

 

STEOR For Men Serum Labskin tests improves skin hydration

Labskin treated with STOER Serum demonstrated a 54% increase in skin hydration after 24 hours and 22% higher after 48 hours.  This effect was seen in the lower layers of the epidermis and at the junction with the dermis, not just the surface.  The depth of hydration seen in results of this study validate the long-term effects of using the STOER Serum.

 

STEOR Power Mask Labskin test packs a punch

The hydration of Labskin treated with STOER Power Mask was 63% higher after 24 hours and 34% higher after 48 hours.  As with the STOER Serum, this effect was seen in the lower layers of the epidermis and at the junction with the dermis, not just the surface, demonstrating a long-lasting effect on the skin.

 

Gerard Brandon, Chief Executive Officer, commented:

"Integumen's strategy is to provide a unique animal-free skin testing platform to test and validate product effects in the pharma, healthcare and beauty industries.  Since the beginning of the year, Labskin has demonstrated the ability to substantiate accurate skin care product claims beyond the usual 74% of women or men.  We work with our skin care partners who are constantly looking for that competitive edge, to prove the impact of their product claims while maintaining an ethical product on the market. 

 

"Our new Labskin dandruff scalp test not only provides a human skin model in a laboratory setting without the need to test on animals but opens the door to the global hair care market which is expected to reach USD $110.70 Billion by 2024*."

 

* OECD Guidelines for the Testing of Chemicals are a set of internationally accepted specifications for the testing of chemicals decided on by the Organisation for Economic Co-operation and Development. They were first published in 1981.

 

 

** Source: https://www.globenewswire.com/news-release/2018/07/09/1534543/0/en/Global-Hair-Care-Market-Expected-to-Reach-USD-110-70-Billion-by-2024-Zion-Market-Research.html

 

Integumen plc	Gerard Brandon, CEO	+44 (0) 7340 055 643
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974
Turner Pope Investments (TPI) Limited  (Broker)	Andy Thacker	+44 (0) 20 3621 4120

 

 

About Integumen:

Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

 

The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAIIMFTMBJTBLL

Close

×

PowerHouse Energy Group plc

("PowerHouse Energy" or the "Company")

17 April 2019

First Revenue Contract for PowerHouse Energy

PowerHouse Energy Group plc (AIM: PHE), the UK technology company pioneering hydrogen and clean energy production from waste plastic, is pleased to announce that it has signed a binding contract with its exclusive partner, Waste2Tricity Limited (???W2T???), for PHE to provide planning and engineering design services that will, subject to successful outcome, lead to a build contract and  license for use of the DMG?? Technology at the Protos site. The agreement defines the paid scope of works during two stages of planning and engineering. At signature, based on quotations from potential Contractors PHE provisionally anticipates that total revenue from the two stages of the contract will amount to approximately ??400,000 to cover PHE and Contractors costs.

The engineering design services to be provided by PHE for stage one includes specific feedstock analysis and testing including some third party services, site modelling and specific engineering related to the Protos site.  This work will define the parameters for the second stage of the project, the Front End Engineering Design (FEED) contract which it is anticipated will be placed with an Engineering, Procurement & Construction (EPC) contractor, following an agreed review.

The agreement also incorporates Heads of Terms in relation to PHE acting as operational process engineering supplier for the DMG?? Technology at the Protos site, encompassing design rights, build contracts and licensing proposition of its technology.

This contract comprises another step towards achieving Financial Close for the first commercial site utilising PHE???s DMG Technology.

David Ryan, CEO of PowerHouse Energy, commented:

???This is the first revenue generating contract signed by PHE and follows the typical revenue regime we will be following for future developments, recognising that more substantial revenues will arise from IP, Design Rights, and licensing and operational engineering in due course.  This agreement demonstrates that W2T expects that a special purpose vehicle formed by it intends to place a formal order for DMG?? when the Pre-FEED and FEED work is complete. We thank W2T for their commitment and long standing support.???

John Hall, Chairman of Waste2Tricity (Protos) Limited commented:

???This agreement formalises our commitment to implement DMG?? Technology on the Protos site. We are working closely in partnership with Peel Environmental, the overall Protos Energy Hub site owners, to finalise all the design parameters with PHE to take the development to the FEED stage and through to fabrication and construction as soon as practical.???

David Ryan, CEO of PowerHouse Energy, further commented:

???We have delivered this agreement in line with our expectations this quarter and we are thankful to our shareholders who have supported us over the years to develop this ground breaking technology to this point of commercialisation and revenues.

ENDS

For more information, contact:

PowerHouse Energy Group plc                                       Tel: +44 (0) 203 368 6399

David Ryan, Chief Executive Officer

WH Ireland Limited (Nominated Adviser)               Tel: +44 (0) 207 220 1666

James Joyce / Chris Viggor

Turner Pope Investments Ltd (Joint Broker)          Tel: +44 (0) 203 621 4120

Ben Turner / James Pope

Ikon Associates (Media enquiries)                               Tel:    +44 (0) 1483 271291

Adrian Shaw                                                                               Mob: +44 (0) 7979 900733

Notes for editors:

About PowerHouse Energy and DMG technology

PowerHouse Energy has developed a proprietary process technology – DMG?? – which can utilise waste plastic, end-of-life-tyres, and other waste streams to efficiently and economically convert them into syngas from which valuable products such as chemical precursors, hydrogen, electricity and other industrial products may be derived. The PowerHouse technology is one of the world???s first proven, modular, hydrogen from waste (HfW) process.

The PowerHouse DMG?? process can generate in excess of 1 tonne of road-fuel quality H2, and more than 28MW/h of exportable electricity per day.

The PowerHouse process produces low levels of safe residues and requires a small operating footprint, making it suitable for deployment at enterprise and community level.

PowerHouse is quoted on the London Stock Exchange's AIM Market under the ticker: PHE, and is incorporated in the United Kingdom.

For more information see www.powerhouseenergy.net

About Waste2Tricity (Protos) Limited

Waste2Tricity (Protos) Limited (W2TP) is the SPV (Special Purpose Vehicle) for the implementation of energy-from-waste facilities at the Protos site and has been set up by W2T the development partners of PHE.

Waste2Tricity is a structured solutions provider to the energy-from-waste (EfW) sector, an industry supplying increasing amounts of electricity using feedstock diverted from landfill.

Waste2Tricity works with clients and partners to develop, fund and support EfW deployment projects that use proven technology, are profitable and progressive; projects that currently use high temperature gasification and either steam cycle or internal combustion engines/gas turbines (ICEs/GTs) to efficiently convert waste to energy.

For more information see www.waste2tricity.com

About Peel Environmental and Protos

Peel Environmental, part of Peel Land and Property (Peel L&P), owns and develops waste infrastructure projects. It has achieved consent for a range of energy infrastructure schemes including a 35MW Energy from Waste plant at Protos in Cheshire, 21MW Energy from Waste plant and 250,000tpa AD and MRF in Glasgow; and a 20MW Energy Centre at Houghton Main, Barnsley. Peel works with investors, waste management companies, technology providers and contractors to secure a deliverable business model for each project.

Peel Environmental brought forward and consented the Protos development, previously known as Ince Resource Recovery Park. Protos is the destination of choice for energy, innovation and industry. Boasting unrivalled connections to some of the region???s biggest industrial forces, Protos is a strategic energy hub at the core of the Northern Powerhouse.

The 54ha (134 acres) development site has full outline planning consent and part detailed planning consent for general manufacturing and distribution uses (B1, B2 & B8), as well as a biomass facility and an Energy from Waste facility. Set on the south bank of the Manchester Ship Canal in the North West of England, the site is ideally placed to become an industrial micro-climate, with enviable transport links providing access to UK and International markets and surrounding industrial heartland.

For more information about Protos visit: www.thisisprotos.com

Close

×

RNS Number : 3888W

Online Blockchain PLC

17 April 2019

 

For immediate release

 17 April 2019

 

Online Blockchain PLC

("Online" or the "Company")

Corporate update

New blockchain-based PC gaming product

 

As announced in the recent interim results, Online Blockchain plc (LSE: OBC), a UK blockchain company, has been developing new blockchain-based products and is now pleased to announce the first of these, FreeLoadr, a PC gaming product now in "invite-only" beta testing.

 

FreeLoadr (www.freeloadr.com), is an application for computer games which allows gamers access to PC games for no charge in exchange for running the FreeLoadr application on their personal computer (PC). The user donates "hash power" to earn points, which can then be redeemed for products on the store selection of 2,500 titles.  FreeLoadr already has a large 'user waiting list' from its closed beta testing phase.

 

The FreeLoadr application currently supports computers with an NVIDIA graphics processing unit (GPU). On downloading and running the FreeLoadr application, the user exchanges unused graphic computing power to earn FreeLoadr points. The more powerful the user's PC, the quicker FreeLoadr points can be earned. The Company plans to develop FreeLoadr for crossover into Playstation & Xbox formats.

 

In an exchange of graphics power for points, FreeLoadr uses the donated GPU processing power to mine selected cryptocurrency (with receipts converted by FreeLoadr into fiat currency) and rewards each user with FreeLoadr points. When a FreeLoadr user has earned enough points, they can then be redeemed at no extra cost to the user in the FreeLoadr on-line store, which contains in excess of 2,500 Steam and Origin games (including Anthem and DragonBall FighterZ). The user selects a game title and is then sent an activation code which unlocks the chosen game.

 

OBC are now finalising the last stage of the Beta testing phase of FreeLoadr and plans to launch the product in the UK and North America.

 

Clem Chambers, CEO of Online said:

"Gaming is a valuable and exciting market. OBC had identified this opportunity in the market last year and now we are ready to showcase our products.  With more than 2.2 billion active gamers in the world, the UK gaming sector generated revenue of £3.864bn in 2018, making it larger than music and video combined: Revenue from digital gaming in 2018 accounted for 80% of the UK Digital Games market. Globally the video games industry, in 2018, generated approximately US$135bn. (See "Sources" below)."

 

"We want to use the power of the blockchain to add value to PC gamers and make it possible for them to get the computer game they want using the latent but unused processing power of their PC. FreeLoadr makes this possible for the current generation of gaming computers without the user needing to be a blockchain or programming expert – they just need to download the FreeLoadr software and run it and they are on their way to getting their first game."

 

"Gaming is a fertile and welcoming sector for applications of new technology such as blockchain because gamers are tech-savvy. We believe that computer gaming is a compelling market application for blockchain, that FreeLoadr is an exciting product for both blockchain and computer gaming and we are delighted with its progress."

 

The number of FreeLoadr reward points needed to redeem a game is calculated by FreeLoadr to be equivalent to the game's retail price (based on the value of the cryptocurrency generated by the respective user's GPU). FreeLoadr pays the wholesale price to Steam and Origin for any game downloaded with points redeemed from the FreeLoadr store.

 

Shareholders should note that the development of FreeLoadr is in beta testing stage of development and launch, and further updates will be provided in due course. For further details go to: www.freeloadr.com.

 

A copy of this announcement is available on the Company's website at: www.onlineblockchain.io.

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. The person who arranged for the release of this announcement on behalf of the Company was Clement Chambers, Director.

Enquiries:

For further information please contact: 

Online Blockchain PLC Clement Chambers	+44 (0) 207 070 0909
Beaumont Cornish Limited (Nominated Adviser) www.beaumontcornish.com	+44 (0) 207 628 3396
Roland Cornish/Michael Cornish
Smaller Company Capital Limited (Broker) Jeremy Woodgate	+44 (0) 203 651 2910
Cassiopeia Ltd (Investor Relations) Stefania Barbaglio	[email protected]

 

About Online Blockchain plc (LSE: OBC)

Online Blockchain (www.onlineblockchain.io) is a UK-based incubator and developer of businesses in internet and information-based technologies, including developers, administrators and custodians of blockchains and cryptocurrencies. The Company created ADVFN www.advfn.com and today still has a holding of 17.98% in ADVFN plc. 

 

Online Blockchain plc continues to consider new related opportunities and particularly crypto currencies and blockchain-based opportunities including incubating cryptocurrency start-ups and developing technical innovation in the blockchain space. Led by a team with over two decades of pioneering in tech, Online Blockchain focuses on innovation in cryptocurrency and decentralised ecosystems via various applications of blockchain: incubating cryptocurrency start-ups and developing technical innovation in the blockchain space.

 

Glossary

 

"blockchain" is a distributed public digital ledger in which transactions are recorded chronologically

 

"cryptocurrency" is a digital currency in which encryption techniques are used to regulate the generation of units of currency and verify the transfer of funds, operating independently of any central bank

 

"Hash power" The speed at which a given mining machine operates. 

 

"mining" is the process of using computer hardware to do mathematical calculations for a cryptocurrency network in order to confirm transactions. Miners collect transaction fees for the transactions they confirm and are awarded cryptocurrency for each block they verify

 

Sources:

The selected video games industry data contained in this announcement has been extracted from the following public sources:

 

https://newzoo.com/insights/articles/newzoo-2017-report-insights-into-the-108-9-billion-global-games-market/

 

https://news.sky.com/story/gaming-sector-now-larger-than-video-and-music-combined-11597476

 

http://www.nintendolife.com/news/2019/01/80_percent_of_uk_gaming_revenue_came_from_digital_sales_in_2018_industry_made_almost_p4bn_in_total

 

https://www.gamesindustry.biz/articles/2018-12-18-global-games-market-value-rose-to-usd134-9bn-in-2018

 

 

ENDS

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

UPDXQLFFKZFEBBL

Close

×

RNS Number : 3586V

Avanti Communications Group Plc

08 April 2019

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR"). Upon the publication of this announcement, the inside information is now considered to be in the public domain for the purposes of MAR.

 

 

Avanti Communications Group plc

 

Avanti Communications Signs Long Term Bandwidth Contract with Turksat

 

 

Avanti Communications (AIM: AVN), ("Avanti" or the "Company"), a leading provider of satellite data communications services in Europe, the Middle East and Africa, has signed a long term bandwidth contract with the Turkish communications satellite operator Turksat.

 

Under the contract, Turksat will commit to 1.8 ghz of capacity on Hylas 2 for the next three years with an option to extend for a further 12 months. The contract will commence on 1 June 2019 and revenues will be spread evenly across the life of the contract.

 

Kyle Whitehill, Chief Executive Officer, Avanti Communications said:  "We are delighted to have been able to provide this capacity to Turksat which will cover the whole of Turkey. This is a significant amount of capacity on HYLAS 2 and demonstrates the demand in the regions in which Avanti operates."

 

Cenk Şen, Chief Executive Officer, at Turksat continued: "We are very happy about our partnership with Avanti, as Turksat is a global player in satellite market, this agreement will enable each partner to grow their business significantly with providing high quality solutions to different organisations with a seamless connection."

 

 

 

For further information, please contact:

 

Avanti	Nigel Fox Tel: +44 (0)207 749 1600
Cenkos (Nomad)	Max Hartley/Katy Birkin Tel: +44 207 397 8900
Newgate Communications	Ralph Anderson Tel: +44 20 3757 6883

 

Notes to Editors:

 

About Turksat

 

Türksat Uydu Haberleşme Kablo TV ve İşletme A.Ş. ("Türksat") is one of the world's leading companies providing all sorts of satellite communications through the satellites of Türksat as well as the other satellites. Türksat currently operates three satellites and with its recent investments Turksat will operate six satellites by 2021. Providing services for voice, data, internet, TV, and radio broadcasting through the satellites across a wide area extending from Europe to Asia, Türksat is able to provide flexible solutions aimed at customers' needs in regions where no terrestrial infrastructure is available. Bringing different languages and cultures together by means of its global solutions in satellite communications, Türksat provides cable broadcasting services as well for its domestic subscribers through its existing cable infrastructure. Furthermore, Türksat operates the e-Government Portal within the scope of its information services and conducts projects for the provision of public services electronically.

 

About Avanti Communications

Avanti connects people wherever they are – in their homes, businesses, in government and on mobiles. Through the HYLAS satellite fleet and its partners across 118 countries, the network provides ubiquitous internet service to a quarter of the world's population. Avanti delivers the level of quality and flexibility that the most demanding telecoms customers in the world seek.

 

Avanti is the first mover in high throughput satellite data communications in EMEA. It has rights to orbital slots and Ka-band spectrum in perpetuity that covers an end market of over 1.7bn people.

 

The Group has invested $1.2bn in a network that incorporates satellites, ground stations, datacentres and a fibre ring.

 

Avanti has a unique Cloud-based customer interface that is protected by patented technology.

 

Avanti Communications is listed in London on AIM (AVN: LSE).

www.avantiplc.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTEADLXEDSNEFF

Close

×

RNS Number : 8032U

Sativa Investments PLC

02 April 2019

 

 

Press Release

2nd April 2019

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

 

Sativa Investments PLC

 

 ("Sativa" or "the Company")

 

Sativa begins cannabinoid research with King's College London 

               

Sativa Investments PLC (NEX: SATI), the UK's first medicinal cannabis investment vehicle, has entered into a research agreement with King's College London ("the College") to research the impact of cannabinoids on inflammation and respiratory diseases. 

 

The research will be led by Professor Clive Page OBE PhD Professor of Pharmacology at King's College London.  Professor Page is a world authority on the pharmacology of inflammation and respiratory disease, having published over 250 scientific papers.  He is a Fellow of the Royal Society of Biology and the British Pharmacological Society, and was awarded an OBE in 2017 for his "Services to Pharmacology." 

 

Sativa, which has a medicinal cannabis grower's licence in process through the Home Office Drugs Licensing and Compliance Unit, will, subject to regulatory consent, supply the university, to order, with specific strains of cannabis plants that contain various combinations of the spectrum of at least 113 known cannabinoids.  The Company is able to provide this service through a combination of its commercial agreement with investee business Canada-based Veritas Pharma Inc., which specialises in identifying the optimum cultivation of various strains, and Sativa's own on-site and highly successful testing facility, PhytoVista Laboratories, that has already undertaken over 1,000 forensic tests relating to a wide variety of cannabinoids, and is accredited and recommended by the UK's Cannabis Trades Association ("CTA"). 

 

Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: "With the UK catching up fast in terms of recognising the benefits of medicinal cannabis, in-country research from the globally-recognised King's College London will assist the medical profession, Government and Regulators in their deliberations. 

 

"As the UK's first medicinal cannabis investment vehicle, Sativa remains at the forefront of this fast-developing sector, which effectively mirrors what has been happening in North America since medicinal cannabis was first legalised in Canada in 2001, more than 17 years ago,"

 

The Directors of the Company accept responsibility for the contents of this announcement. 

 

–  Ends –

 

For further information please contact:

 

Geremy Thomas Founder & Chief Executive Officer Sativa Investments PLC +44 (0) 20 7971 1255 [email protected]	Joseph Colliver Chief Financial Officer Sativa Investments PLC +44 (0) 20 7971 1255 [email protected]
NEX Exchange Corporate Adviser Guy Miller and Lucy Williams Peterhouse Capital Limited  +44 (0) 20 7469 0930 [email protected]

 

Financial PR and IR Abchurch Communications Julian Bosdet / Dylan Mark / Alejandra Campuzano Abchurch Switchboard [email protected]

+44 (0) 20 7469 4633 / 4634     +44 (0) 20 7469 4630 www.abchurch-group.com

 

 

Notes to Editors

Sativa invests in well-placed ventures within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company's pan-European, end-to-end, seed-to-consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company's equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

 

Sativa Investments has already made six investments to date, these being Canada-based and dual-listed emerging pharmaceutical company, Veritas Pharma Inc. ("Veritas Pharma" or "Veritas"), CSE-listed Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc. ("RDT"), which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals Ltd (of which Sativa has 100 per cent ownership), PhytoVista Laboratories (of which Sativa also has 100 per cent ownership), a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil, a joint venture with Germany's Lexamed GmbH, and an option on a 7.53-acre development site in Wiltshire with the potential to build a glasshouse for growing raw cannabis for medicinal and CBD use. 

 

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company's Board and Medicinal Cannabis Advisory Board have a combined 60 years' industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency, which he has chaired, for the legalisation of medicinal cannabis in the UK  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativainvestments.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NEXGMGGDVZVGLZG

Close

×

RNS Number : 0820T

EU Supply PLC

18 March 2019

 

18 March 2019

EU Supply plc

("EU Supply", the "Company" or the "Group")

 

Contract win

 

EU Supply (LSE AIM: EUSP), the e-procurement software provider, is pleased to announce that it has signed a contract with a service provider that facilitates cost effective services and solutions for collaboration and information sharing within the oil and gas sector for the delivery of some initial services for their supplier qualifications.

 

Commenting, Thomas Beergrehn, CEO of EU Supply, said:

"We are pleased to announce the signing of this maiden agreement in the oil and gas sector. It is a sector with significant needs in both qualification, tendering, contract management and risk management. We believe this first inroad in the oil and gas sector may lead to considerable additional business in the next three years."

 

 

FURTHER ENQUIRIES

EU Supply PLC Tel: 020 7127 4545 Thomas Beergrehn, CEO   Fredrik Wallmark, CFO       Stockdale Securities Tel: 020 7601 6100 Tom Griffiths, David Coaten

 

A copy of this announcement is available at www.eu-supply.com.

 

Notes to Editors

EU Supply is the UK holding company of the EU Supply Group, a Sweden-based e-commerce business, which has an established, market-leading, multilingual e-procurement platform for e-sourcing, e-tendering and contract management, tailored for the highly regulated European public sector market.

Since 2006, the Group has invested heavily in employing specialist programmers to add functionality, legal compliance as required and security features to its Complete Tender Management™ ("CTM™") platform to ensure that the Group is ideally placed to secure new contracts with EU Member States and their Contracting Authorities. The platform is available in 16 different languages.

The Directors believe that the Group's CTM™ platform is one of the easiest to use and most functionally advanced solutions available in the market. The CTM™ platform is used by over 8,000 European public sector bodies in 9 EU/EEC Member States and has National Procurement System status in four Member States (the UK, Ireland, Norway and Lithuania).

The Company's shares were admitted to trading on AIM in November 2013. In August and September 2015, the Company raised a total of £2.061m (before expenses) through a placing of new shares and the issue of first and second tranches of Convertible Loan Notes to institutional and other investors. On 25 May 2018, the Company announced that it had raised a further £600k (before expenses) through a placing and subscription of new shares.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAQELFFKXFZBBD

Close

×

RNS Number : 8065R

EU Supply PLC

05 March 2019

 

5 March 2019

EU Supply plc

("EU Supply", the "Company" or the "Group")

 

Contract wins

 

EU Supply (LSE AIM: EUSP), the e-procurement software provider, is pleased to announce strong demand in its target markets for 2019.

 

In particular, the Company has been awarded the following contracts with new clients in both Denmark and Germany:

·     A new procurement service provider in Denmark, which is live with the Company's CTMTM solution.

·     Two new clients in the Danish public sector, which were awarded following competitive tender processes, both of which migrated from a competitor's solution and are live with the Company's CTMTM solution.

·     Two new clients in Germany, one of which is now live with Company's CTMTM solution.

 

In addition, the Group has configured its solution for use in the tendering process for the Femern Tunnel, which is proposed to connect Denmark and Germany and is believed will become the longest combined rail and road tunnel worldwide. The overall construction phase is expected to be 8 to 9 years. Some of Europe's largest contractors and contract managers are expected to be involved. The first tenders for the project have been published on the Company's CTMTM platform.

 

FURTHER ENQUIRIES

EU Supply PLC Tel: 020 7127 4545 Thomas Beergrehn, CEO   Fredrik Wallmark, CFO       Stockdale Securities Tel: 020 7601 6100 Tom Griffiths, David Coaten

 

A copy of this announcement is available at www.eu-supply.com.

 

Notes to Editors

EU Supply is the UK holding company of the EU Supply Group, a Sweden-based e-commerce business, which has an established, market-leading, multilingual e-procurement platform for e-sourcing, e-tendering and contract management, tailored for the highly regulated European public sector market.

Since 2006, the Group has invested heavily in employing specialist programmers to add functionality, legal compliance as required and security features to its Complete Tender Management™ ("CTM™") platform to ensure that the Group is ideally placed to secure new contracts with EU Member States and their Contracting Authorities. The platform is available in 16 different languages.

The Directors believe that the Group's CTM™ platform is one of the easiest to use and most functionally advanced solutions available in the market. The CTM™ platform is used by over 8,000 European public sector bodies in 9 EU/EEC Member States and has National Procurement System status in four Member States (the UK, Ireland, Norway and Lithuania).

The Company's shares were admitted to trading on AIM in November 2013. In August and September 2015, the Company raised a total of £2.061m (before expenses) through a placing of new shares and the issue of first and second tranches of Convertible Loan Notes to institutional and other investors. On 25 May 2018, the Company announced that it had raised a further £600k (before expenses) through a placing and subscription of new shares.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRABIGDXRDGBGCS

Close